VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 26, 2007) - Chemokine Therapeutics Corp. (the “Company”) (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that a poster presentation covering preliminary results from the CTCE-9908 Phase I/II clinical trial was presented by Dr. Sebastien Hotte, Lead Investigator, at the Molecular Targets and Cancer Therapeutics International Conference being held this week in San Francisco, California.
